Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kaylan Pustover

Dermatology New York, NY Doctor of Osteopathy

NPI 1871901918 CMS profile 673305

4 W 58Th St Fl 13, New York, NY 10019

Open in the dashboard

General payments

$8,535

468 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kaylan Pustover of New York, NY is reported in the CMS Open Payments database as having received $8,535 across 468 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,616 96
2024 General $1,139 58
2023 General $1,361 68
2022 General $1,106 68
2021 General $1,220 55
2020 General $815 40
2019 General $1,278 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kaylan Pustover
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Kaylan Pustover were reported at $1,616. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Kaylan Pustover Dermatology median Middle half National median
2019 $1,278 $454 $129–$1,240 $163
2020 $815 $235 $81–$756 $114
2021 $1,220 $377 $108–$1,108 $132
2022 $1,106 $514 $143–$1,391 $149
2023 $1,361 $607 $159–$1,674 $160
2024 $1,139 $751 $204–$1,903 $164
2025 $1,616 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,181 60 payments
  2. Galderma Laboratories, L.P. $1,158 54 payments
  3. Janssen Biotech, Inc. $1,014 69 payments
  4. Incyte Corporation $774 66 payments
  5. Ortho Dermatologics, a division of Bausch Health US, LLC $601 37 payments
  6. Mayne Pharma Inc. $499 36 payments
  7. Novartis Pharmaceuticals Corporation $493 22 payments
  8. Regeneron Healthcare Solutions, Inc. $424 18 payments
  9. Genzyme Corporation $339 13 payments
  10. Lilly USA, LLC $203 10 payments
  11. Other $1,850 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,245 465 payments
  2. Education $290 3 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $944 65 payments
  2. OPZELURA $774 66 payments
  3. SKYRIZI $665 32 payments
  4. AKLIEF $575 20 payments
  5. EPIDUO FORTE $520 24 payments
  6. DUPIXENT Immunology $518 17 payments
  7. ORACEA $483 20 payments
  8. COSENTYX $367 15 payments
  9. DUPIXENT Inflammation And Immunology $332 15 payments
  10. DORYX $318 26 payments
  11. Other $5,207 263 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Dermatology: 534

Drug cost

$153

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Minoxidil Generic 13 $153

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $266
$266 — —
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $100
  • GENZYME CORPORATION $54
  • Regeneron Healthcare Solutions, Inc. $28
$182 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $171
$171 — —
SKYRIZI
  • AbbVie, Inc. $141
$141 — —
ADBRY
  • LEO Pharma Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

468 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record